Rationality: T2DM is a component of the metabolic syndrome, the occurrence of overweight, arterial hypertension (AH), and dyslipidemia in T1DM is variable according to the literature.
Objective: Study of the occurrence of overweight, AH and dislipidemy in T1DM
Materials and methods: Total 726 patients with T1DM (348m, 378f), mean age (M±σ) 34.71±0.58 yrs (178), age of T1DM manifestation 12.41±0.36 yrs and special form including questions about T1DM. Levels of triglycerides (TRIG), total cholesterol (CHOL), high density lipoprotein (HDL), low density lipoprotein (LDL), very low density lipoprotein (VLDL) and HbA1C (%) were measured by biochemical analyzer ARCHITECT C8000 (Abbott, USA). Body mass index (BMI), systolic blood pressure (sBP), diastolic blood pressure (dBP) were analysed. Control includes 206 healthy volunteers of similar age and sex.
Results: The levels of sBP, dBP, HbA1C, TRIG and LDL were significantly higher in T1DM, than in the control (*P<0.001). Differences of rates are fixed in patients in their division into age categories: under 18, 18 and over (table -^P<0.001).
BMI of 2529.9 kg/m2 was recorded in 188 patients (31%) and 41 subjects of control (28%), BMI of 3034.9 kg/m2 in 89 patients (14%) and 16 subjects of control (11%), BMI of 3539.9 kg/m2 in 25 patients (4%) and 5 subjects of control (4%), BMI of 40 kg/m2 and more (obesity of the third degree) in 5 patients (1%) and 6 subjects of control (4%). The levels of sBP, dBP, CHOL, TRIG and LDL (P=0.001) were higher and the level of HDL was lower (P=0.015) in the presence of T1DM and overweight, such differences occurred in men and women.
Conclusion: The patients over 18 with T1DM have often AH, dislipidemy, overweight and obesity. The patients with overweight and T1DM had high BP (>130/80 mm Hg) and metabolic changes in the form of atherogenic shifts in blood lipid spectrum. That indicates the risk increase of cardiovascular diseases.
Declaration of interest: The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research project.
Funding: This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.
|Indicator||T1DM total||T1DM under 18||T1DM 18 and over||Control group|
|Chol,mmol/l||4,7 [4,0/5,5]||4,2 [3,7/4,7]^||4,8 [4,1/5,6]||4,7 [3,9/5,5]|
|TRIG, mmol/l||1,1 [0,7/1,5]*||0,8 [0,6/1,2]^||1,1 [0,8/1,7]||0,9 [0,6/1,3]|
|HDL, mmol/l||1,5 [1,2/1,8]||1,5 [1,2/1,7]||1,4 [1,2/1,7]||1,3 [1,1/1,5]|
|LDL, mmol/l||3,1 [2,5/4,2]*||2,7 [2,3/3,2]^||3,2 [2,6/4,3]||2,9 [2,3/3,4]|
|sBP, mm Hg||120,0[110,0/140,0]*||100,0[100,0/110,0]^||120,0[120,0/140,0]||110,0[100,0/130,0]|
|dBP, mm Hg||80,0 [70,0/90,0]*||70,0 [60,0/70,0]^||80,0 [75,0/90,0]||70,0 [60,0/80,0]|
|HbA1c, %||8,5 [7,3/10,4]*||9,3 [7,6/11,3]^||8,4 [7,3/10,2]||5,1 [4,9/5,3]|
05 - 09 May 2012
European Society of Endocrinology